Medical treatment of ectopic pregnancy (EP) is based on the administration of methotrexate (MTX). It concerns ectopic pregnancy with β-hCG <10000 without cardiac activity and applies to women informed, without history of ectopic pregnancy and who understand the predictive signs of break. These women should always be monitored until β-hCG negativity. The risk of tubal break persists throughout the treatment with MTX. The authors report three cases of ectopic pregnancy treated medically and whose evolution has been marked by a break. They talk through these cases about the indications and limitations of medical treatment and the risks of tubal break under medical treatment.
Trastuzumab is the first target molecule designed for breast cancer treatment. In first-line metastatic, trastuzumab in combination with chemotherapy significantly improved survival of patients bearing HER2-positive breast cancer. In adjuvant trastuzumab was tested in several randomized trials. In contemporary literature, many strong arguments confirm the clear survival benefit of trastuzumab in adjuvant administered concomitantly with taxane-based chemotherapy and concomitant with radiation therapy, and for a period of one year.
The authors report a case of hydrops fetalis discovered incidentally during a morphological ultrasound performed at 23 weeks of gestation in a 31 years old primigravida woman. The etiology was an infection by parvovirus B19. What is special about our observation is firstly that fetal infection by parvovirus B19 in pregnancy is rare and responsible of fetal anemia. Besides, thanks to a multidisciplinary care including obstetricians, neonatologists, anesthetists and after two transfusions, our patient was conducted pregnancy up to 34 weeks of gestation and give birth by caesarean section of a newborn female.